Toronto-based Lorus Therapeutics saw its stock price plunge 45 percent after the company reported that Virulizen for pancreatic cancer did not hit its primary endpoint in a Phase III trial. "While comparison of the median overall survival times did not reach statistical significance, exploratory analysis did show promising trends in specific patient populations," Lorus stated. Article